ABILITYPHARMA

Ability Pharmaceuticals is a clinical stage drug discovery and development biopharmaceutical company

PIPELINE

ABTL0812, first-in-class, is currently in phase 2 clinical trials in lung cancer and endometrial cancer patients in Spain and France

SCIENCE

AbilityPharma investigates cancer drugs inducing autophagy by binding receptors PPARα/γ

ONE MILLION EUROS CROWDFUNDING CAMPAIGN WITH CAPITAL CELL COMPLETED

PHASE 2 CLINICAL TRIAL ONGOING AS FIRST-LINE THERAPY IN PATIENT WITH EITHER ADVANCED/METASTATIC ENDOMETRIAL CANCER OR LUNG CANCER. PATIENTS BEING RECRUITED AT VALL D'HEBRON INSTITUT D'ONCOLOGIA VHIO (BARCELONA), INSTITUT GUSTAVE ROUSSY IGR (PARIS), INSTITUT CATALÀ D'ONCOLOGIA ICO (L’HOSPITALET, BADALONA AND GIRONA), CENTRE LÉON BÉRARD (LYON), INCLIVA (VALENCIA), INSTITUT PAOLI-CALMETTES (MARSEILLE) AND HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO (SEVILLE).

AbilityPharma is a biopharmaceutical company focused on creating the future of oncology by developing innovative therapies that address unmet medical needs. The company was established in 2009 with one product, ABTL0812, an oral autophagy-inducer targeted therapy in phase 2 clinical trials in patients with endometrial cancer and in squamous NSCLC.

Media Center

31.05.2019

News

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

News

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
06.06.2019

Publications

Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma + info
09.04.2019

Publications

Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. + info
June.2019

Events

BIO International. Philadelphia (USA) + info
June.2019

Events

ASCO Annual Meeting. Chicago (USA) + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG